Getty Images
May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company.
Sarah Bundra, Pharmaceutical Analyst at GlobalData, commented: “Mavacamten will be the first drug to specifically target obstructive HCM, which is a common form of cardiomyopathy. It has a unique mechanism of action (MoA)—being a myosin inhibitor—that more closely targets the pathophysiology of the disease.”
Existing cardiomyopathy therapies are generic and used for a wide range of cardiovascular diseases. Mavacamten can be used in conjunction with marketed therapies, such as beta blockers. As such, the drug will not displace any current therapy options, but will address a key cardiomyopathy demographic that has not previously been the target of clinical trial development.
Mavacamten’s performance in the VALOR-HCM study—whereby only 18% of participants still needed surgical intervention after 16 weeks—highlight its strength and potential in this market. This is even more impressive compared to placebo, of which 77% still needed surgery after the same time frame. Mavacamten has proved it can offer patients a chance to avoid invasive and costly procedures. Other reports from the VALOR-HCM study show that the majority of patients requested to continue the drug after the 16-week study period, suggesting a favorable safety profile.
Bundra adds: “Dr. Desai’s VALOR-HCM study results give obstructive HCM patients reasons to be excited.”
For more information: https://www.globaldata.com/
More ACC22 coverage can be found here
Related content:
Cardiogenic Shock Market Outlook
ACC22: Transforming Cardiovascular Care
FDA Approves Bristol Myers' Camzyos (mavacamten) Oral Heart Disease Drug
July 31, 2024 
